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Abstract Purpose: Gene expression analysis identifies several breast cancer subtypes.We examined the
relationship of neoadjuvant chemotherapy response to outcome among these breast cancer sub-
types.
Experimental Design:Weused immunohistochemical profiles [human epidermal growth factor
receptor 2^ positive (HER2+)/hormone receptor ^ negative for HER2+/estrogen receptor ^
negative (ER), hormone receptor and HER2 for basal-like, hormone receptor ^ positive for
luminal] to subtype a prospectively maintained data set of patients with breast cancer treated
with neoadjuvant anthracycline-based (doxorubicin plus cyclophosphamide, AC) chemotherapy.
We analyzed each subtype for clinical andpathologic response toneoadjuvant chemotherapy and
examined the relationship of response to distant disease ^ free survival and overall survival.
Results:Of the107 patients tested, 34 (32%)were basal-like,11 (10%)were HER2+/ER, and
62 (58%) were luminal. After neoadjuvant AC, 75% received subsequent chemotherapy and all
received endocrine therapy if hormone receptor ^ positive. The chemotherapy regimen and
pretreatment stage did not differ by subtype. Clinical response to AC was higher among the
HER2+/ER (70%) and basal-like (85%) than the luminal subtypes (47%; P < 0.0001).
Pathologic complete response occurred in 36% of HER2+/ER, 27% of basal-like, and 7% of
luminal subtypes (P = 0.01). Despite initial chemosensitivity, patients with the basal-like and
HER2+/ER subtypes had worse distant disease ^ free survival (P = 0.04) and overall survival
(P = 0.02) than those with the luminal subtypes. Regardless of subtype, only 2 of 17 patients
with pathologic complete response relapsed. The worse outcome among basal-like and HER+/
ER subtypes was due to higher relapse among those with residual disease (P = 0.003).
Conclusions: Basal-like and HER2+/ER subtypes are more sensitive to anthracycline-based
neoadjuvant chemotherapy than luminal breast cancers. Patients that had pathologic complete
response to chemotherapy had a good prognosis regardless of subtype. The poorer prognosis
of basal-like and HER2+/ER breast cancers could be explained by a higher likelihood of relapse
in those patients in whom pathologic complete response was not achieved.
Gene expression studies have identified three major subtypes
of breast cancer (basal-like, HER2+/ER, and luminal; ref. 1)
that have differing prognoses (2). A particularly poor outcome
is seen among the two hormone receptor–negative subtypes
(i.e., basal-like and HER2+/ER), compared with the hormone
receptor–high luminal group (2, 3). Evidence suggests that the
effect of improved adjuvant chemotherapy is greater among
hormone receptor–negative breast cancer (4). A recent report
revealed significantly higher pathologic complete response to
neoadjuvant chemotherapy among basal-like and HER2+/ER
subtypes compared with luminal subtypes (5). If so, this raises
the question of whether the traditional perspective of patho-
logic complete response as a proxy for relapse and survival
holds true across each subtype. In this study, we used
immunohistochemistry to classify tumors according to breast
cancer subtype and examined the relationship between neo-
adjuvant response and long-term end points, including distant
disease–free survival (DDFS) and overall survival (OS).
Materials andMethods
Patients and treatments. This cohort included patients with stage II
and III breast cancer who received neoadjuvant doxorubicin (60mg/m2)
plus cyclophosphamide (600 mg/m2) chemotherapy (AC) given i.v.
for four cycles, either alone, or as the first component of a sequential
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AC-taxane neoadjuvant regimen. One hundred and seven patients who
received neoadjuvant AC and from whom estrogen receptor (ER),
progesterone receptor (PR), human epidermal growth factor receptor 2
(HER2), and response data were available were identified through
the University of North Carolina, Lineberger Comprehensive Cancer
Center Neoadjuvant Database, which is a database of all patients treated
with neoadjuvant therapy that is updated every 6 months and includes
serial clinical, radiographic, and pathologic tumor measurements,
treatment details, and outcome. Patients included in this data set were
treated between June 1998 and October 2003.
Molecular classification. The best way to perform breast tumor
intrinsic subtyping is to use microarrays for gene expression analysis,
however, most archived clinical specimens are not amenable to
microarray analysis and other methods must be employed. We
previously showed that a combination of immunohistochemical
markers could be used for molecular subtyping (6). A combined
analysis of the data presented in Nielsen et al. (6) and Livasy et al. (7)
on the subset of samples in which we had both gene microarray data
and immunohistochemistry for ER and HER2 revealed that the basal-
like subtype was largely ER (32 of 34) and HER2 (all 34), the
HER2+/ER subtype was ER (all 12) and HER2+ (11 of 12), and the
luminal subtype (luminal A and B combined) was ER+ (24 of 24); thus,
on this combined set of 70 tumors, 94% of basal-like, 92% of HER2/
ER, and 100% of luminal tumors would have been correctly identified
using a simple ER and HER2 scoring method. For this study, we used
these immunohistochemical surrogates taken from the clinical data and
defined the basal-like subtype as ER, PR, and HER2, the HER2+/
ER subtype as ER, PR, and HER2+, and the luminal A and B
subtypes were combined into a single luminal group defined by either
ER or PR positivity, regardless of other characteristics. In hierarchical
clustering analyses, there are at least two subgroups of luminal breast
cancers, i.e., luminal A and B. Because hormone receptor–positive/
HER2+ tumors are generally luminal B (2, 3), we have also analyzed
them subcategorized as luminal B here, as was done in a previous
publication (8); hormone receptor–positive/HER2 tumors are
designated as luminal A. However, it is important to recognize that
hormone receptor–positive/HER2+ tumors comprise a minority of
luminal B, so this method of subcategorizing the luminal subtypes will
necessarily misclassify a substantial fraction of luminal B tumors into
the luminal A category. The ER and PR were scored positive at
University of North Carolina if at least 5% of the invasive cells showed
staining. HER2 immunohistochemistry used CB11 antibody until 1998,
until the DAKO Herceptest was used (DAKO, Carpinteria, CA). Prior to
2000, HER2 was scored positive if a 2+ or 3+ result was found, after
2000, a 2+ result was only positive if confirmed by fluorescence in situ
hybridization for gene amplification.
Clinical response and statistical methods. Clinical response was
measured according to the Response Evaluation Criteria in Solid
Tumors (9). In those patients with tumors that were clinically dif-
ficult to measure, radiographic response to therapy was substituted
for clinical response. In all patients, only one method of tumor
measurement was used. Whenever possible, tumor measurements were
obtained from the same physician. Pathologic response to chemo-
therapy was assessed by posttreatment American Joint Committee
on Cancer tumor-node-metastasis staging for invasive carcinoma
only (10).
Fisher exact test was used to evaluate possible associations between
subtypes and the nominal and dichotomized covariates (i.e., race, dose
density, and whether or not adjuvant endocrine therapy was given,
etc.). When at least one of the comparing variables was ordinal (such as
stage of disease, clinical, and pathologic response), the nonparametric
Jonckheere-Terpstra method was used to test for ordered differences
among categories. With this test, the null hypothesis is that the
distribution of the response does not differ across ordered categories.
The Kruskal-Wallis test (using Van der Waerden normal scores) was
used to evaluate possible differences in responses between subtypes and
the continuous covariate of age. Logistic regression was used to evaluate
the association of age, race, disease stage, HER2+/ER versus luminal
subtypes, and basal-like versus luminal subtypes with clinical response
(complete response or partial response versus not complete response or
partial response).
Two types of time-to-event analyses were done: DDFS and OS. DDFS
was calculated as the time from the date of diagnosis of the primary
tumor to the date of the development of distant or regional metastases,
date of death from any cause, or the date of last contact. This definition
of DDFS did not include recurrences in a conserved breast, the axilla,
or on the chest wall. OS was calculated as the time from the date of
diagnosis of the primary tumor to the date of death from any cause, or
the date of last contact. The Kaplan-Meier (or product limit) method
was used to estimate the DDFS and OS survivorship functions. The
Wilcoxon method (also known as the Gehan or Breslow test) was used
to compare time-to-event curves. This test was chosen because of the
way it is calculated; it places more emphasis on earlier differences
between curves. Statistical analyses were done using JMP version 5 and
SAS Statistical Software, version 9.1, both products of the SAS Institute,
Inc. (Cary NC). This study was approved by the University of North
Carolina at Chapel Hill Committee on the Protection of the Rights of
Human Subjects.
Results
Patient and tumor characteristics. Table 1 shows the charac-
teristics of the patients in this study. Patients with basal-like,
HER2+/ER, and luminal subtypes of breast cancer did not
differ significantly by age, race, or disease stage (P = 0.17,
P = 0.15, and P = 0.56, respectively). All patients received
AC neoadjuvant chemotherapy at conventional doses for
four cycles. Twenty-eight (26%) received AC on a dose-
dense schedule (every 2 weeks), whereas the rest of the
patients received AC on an every 3 weeks schedule. The use
Table 1. Patient characteristics
All patients Basal-like HER2+/ER Luminal B* Luminal A P
N (%) 107 34 (32%) 11 (10%) 26 (24%) 36 (34%)
Median age (range) 51 (27-79) 45 (27-69) 49 (30-79) 51.5 (32,77) 52.5 (31,64) 0.17
Race
African-American 36 (34%) 16 (47%) 5 (45%) 5 (19%) 10 (28%) 0.15
Caucasian 68 (63%) 17 (50%) 6 (55%) 21 (81%) 24 (67%)
Other 3 (3%) 1 (3%) 0 0 2 (5%)
Stage II 42 (39%) 12 (35%) 3 (27%) 10 (38%) 17 (47%) 0.26
Stage III 65 (61%) 22 (65%) 8 (73%) 16 (62%) 19 (53%)
*ER+ or PR+, HER2+.
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of the dose-dense schedule did not differ among tumor
subtypes (P = 0.46). Most patients (80 of 107, 75%) received
additional neoadjuvant chemotherapy following AC, which
primarily involved either paclitaxel or docetaxel (79 of 80, or
99%). One patient received only one cycle of taxane, which was
poorly tolerated, and completed the remainder of her post-AC
chemotherapy with vinorelbine. It is worth noting that clinical
response rates reflect only the AC contribution, whereas
pathologic response rates reflect both the AC and subsequent
neoadjuvant regimens. Adjuvant endocrine therapy was given
to 3 of 34 (9%) patients with basal-like, 0 of 11 patients with
HER2+/ER, and 61 of 62 (98%) patients with luminal tumor
(P < 0.0001) subtypes.
Clinical and pathologic response to neoadjuvant anthracycline.
Table 2 illustrates the clinical response to AC, and the patho-
logic response to all neoadjuvant therapies. Clinical response
assessments were done after AC and did not reflect the effect
of subsequent sequential drugs. Clinical response to AC
differed significantly among the subtypes (P < 0.0001), with
HER2+/ER and basal-like subtypes showing higher clinical
response rates than luminal subtypes. This difference
remained when evaluating a collapsed table comparing the
dichotomized proportion of complete and partial responses
to the rest (P < 0.0001). The greatest difference was seen
between luminal A (39%) and basal-like (85%) subtypes.
Logistic regression was used to evaluate the association of age,
race, disease stage, HER2+/ER versus luminal subtype, and
basal-like versus luminal (A + B combined) subtypes relative
to clinical response (complete response or partial response
versus not complete response or partial response); of these,
only basal-like versus luminal was significant (odds ratio, 6.6;
95% confidence interval, 2.26-19.28).
As mentioned above, most patients received subsequent
taxane-based chemotherapy after AC that would not contribute
to the clinical response, but may have contributed to the
pathologic response. Patients who were stage II (20 of 42,
48%) were significantly more likely to receive AC alone than stage
III (7 of 65, 11%; P < 0.0001). Additional chemotherapy was
received by 26 of 34 (76%) patients with basal-like tumors, 10 of
11 (90%) HER2+/ER, and 44 of 62 (71%) with luminal tumors
(21 of 26 luminal B, and 23 of 36 luminal A). These differences
were not significant. Three of the patients did not undergo
primary surgery and thus do not have pathologic data available.
Pathologic complete response was higher in those that received
subsequent chemotherapy (16 of 79, 20%) than those that did
not (1 of 25, 4%; P = 0.04); the use of subsequent chemotherapy
was discretionary, which limits the interpretability of this












Clinical response to AC
Complete response 15 (14%) 10 (29%) 1 (10%) 2 (8%) 2 (6%) <0.0001
Partial response 50 (47%) 19 (56%) 6 (60%) 13 (50%) 12 (33%)
Stable disease 40 (38%) 5 (15%) 3 (30%) 11 (42%) 21 (58%)
Progressive disease 1 (1%) 0 0 0 1 (3%)
Complete response + partial response 65 (61%) 29 (85%) 7 (70%) 15 (58%) 14 (39%) <0.0001
Pathologic stage post-chemotherapy 0.0004
0 17 (16%) 9 (27%) 4 (36%) 4 (15%) 0
I 26 (25%) 10 (31%) 1 (9%) 8 (31%) 7 (21%)
II 33 (32%) 8 (24%) 5 (46%) 8 (31%) 12 (35%)
III 27 (26%) 6 (18%) 1 (9%) 5 (19%) 15 (44%)
IV 1 (1%) 0 0 1 (4%) 0
*One patient with the HER2+/ER subtype was not evaluable for clinical response, and three patients did not undergo primary surgery.
Fig. 1. DDFS (A) and OS (B) according to breast cancer subtype.
Chemosensitivity and Outcome in Breast Cancer Subtypes
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difference. Pathologic complete response to chemotherapy was
significantly better among basal-like (27%) and HER2+/ER
(36%) subtypes versus the combined luminal subtypes (7%;
P = 0.01). Four of 26 (15%) luminal B tumors had pathologic
complete response, but there were no pathologic complete
responses among 34 patients with luminal A tumors that
underwent surgery (P = 0.03). In addition, the percentage of
patients with minimal residual disease (stage 0-I) after chemo-
therapy was higher among basal-like (19 of 33, 58%) than
HER2+/ER (5 of 11, 45%) or luminal subtypes [luminal B (12
of 26, 46%) and luminal A (7 of 34, 21%); P = 0.002].
Long-term end points. The median follow-up time for the
survivors in this cohort wasf39 months. In this patient set, 21
(20%) relapsed and 19 (18%) died, and there were 23 alive
more than 5 years from diagnosis. The Kaplan-Meier method
was used to estimate time-to-event functions. Figure 1 illustrates
a significant difference in DDFS (P = 0.04) and OS (P = 0.02)
among the subtypes (results were similar when obtained
whether classified as three groups or four groups with luminal
A and B categories). The estimated 4-year DDFS (with 95%
confidence limits) were: basal-like, 71% (51-84%); HER2+/
ER, 51% (18-77%); and luminal (A + B combined), 82%
(64-91%); with luminal A being, 84% (52-95%); and luminal B
being, 78% (54-90%). As illustrated in Fig. 1, the difference
between subtypes was particularly apparent early; all the
relapses after 40 months occurred in only the luminal cancers.
Only 2 of the 17 patients (one with the HER2+/ER subtype,
one with the luminal B subtype) with pathologic complete
response to neoadjuvant chemotherapy relapsed, and none died
(Fig. 2; P = 0.30). To further examine the relationship between
outcome and pathologic complete response, we tested the
outcomes of the subtypes after removing all patients that
achieved a pathologic complete response and determined that
a poorer outcome was seen among the basal-like and HER2+/
ER subtypes compared with luminal subtypes; this seems to
be due to a greater likelihood of relapse or death among those
with residual disease following neoadjuvant chemotherapy
(P = 0.003; Fig. 3).
The most common site of initial relapse was bone, which was
involved in 9 of 20 (45%) patients. Other sites (in order of
frequency) included: lymph nodes (4, 20%), central nervous
system (4, 20%), lung or pleura (2, 10%), and liver (1, 5%).
Discussion
Gene expression analyses have identified molecular subtypes
that are refining our understanding of breast cancer biology.
The luminal subtypes make up the vast majority of the
hormone receptor–positive tumors, whereas the basal-like
and HER2+/ER subtypes make up the majority of hormone
receptor–negative cancers. The poor outcomes seen among
basal-like and HER2+/ER subtypes has been reported
previously (2, 3); however, it has not been clear if this poor
outcome was due their biology, or resistance to systemic
therapy, or some combination of the two.
Response to neoadjuvant chemotherapy was related to
subsequent disease-free and overall survival (10–12), thus
Fig. 2. DDFS of the entire cohort comparing those patients that achieved
pathologic complete response and those that had residual disease after
neoadjuvant anthracycline-based chemotherapy. Regardless of subtype, only two
relapses occurred among those with pathologic complete response to neoadjuvant
chemotherapy at 39 mo of follow-up (P = 0.30; A). DDFS of the cohort excluding
luminal A illustrates the relationship between pathologic complete response and
outcome among those most affected by chemotherapy (P = 0.09; B).
Fig. 3. DDFS among those patients with residual disease after neoadjuvant
chemotherapy by breast cancer subtype. If pathologic complete response was not
achieved, basal-like and HER2+/ER subtypes had a higher risk of subsequent
relapse compared with the luminal subtypes.
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making this a valuable intermediate end point for the
evaluation of novel agents or combinations. We examined
whether this end point varied by subtype in the presence of
neoadjuvant chemotherapy and determined that the luminal
subtypes had a significantly lower clinical and pathologic
response relative to the basal-like and HER2+/ER subtypes.
Despite higher chemosensitivity to conventional anthracycline-
based chemotherapy, the basal-like and HER2+/ER subtypes
still showed worse survival due to higher relapse among those
with residual disease after chemotherapy.
Previous reports have suggested that ER+ tumors have a poorer
response to primary chemotherapy than ER tumors (13, 14).
In a study limited to ER+ tumors only, the pathologic complete
response rate to combination anthracycline and taxane neo-
adjuvant chemotherapy was a mere 7% (15), which was
similar to the frequency in the combined luminal A + B
(hormone receptor–positive) tumors observed here. A different
anthracycline-taxane regimen in HER2-overexpressing tumors,
whether ER+ or ER, revealed a pathologic complete response
rate of 25% (16). That study included both hormone receptor–
negative tumors (HER2+/ER subtype) and hormone receptor–
positive tumors (luminal B subtype here). A recently reported
study using gene expression profiling and a similar molecular
classification that was used here also showed that both basal-
like and HER2+/ER subtypes have high pathologic response
to therapy (5). Our study, using immunohistochemical proxies
for the subtypes, confirms these findings and extends them
through the use of long-term end points to explain the paradox
of better pathologic complete response rates but worse survival
driven by higher relapse rates among those tumors that were
not eradicated by the chemotherapy.
There are multiple potential reasons that the response to
chemotherapy differed by subtype. The basal-like and HER2+/
ER breast cancer subtypes are characterized by the high
expression of the proliferation cluster of genes (2), which is
mirrored by other more conventional indexes of proliferation
as well. A prognostic index that is heavily influenced by
proliferation genes was recently shown to predict pathologic
complete response to doxorubicin/docetaxel primary chemo-
therapy (17), lending credence to the relationship of prolifer-
ation to chemosensitivity.
The paradox of higher sensitivity to neoadjuvant anthracy-
cline in subtypes known to have a poor prognosis is explained
by the high relapse among those with residual disease.
Reassuringly for clinical trial designs that use pathologic
complete response as an intermediate end point, the relation-
ship of pathologic complete response to survival was main-
tained across patients and subtypes in this study. Specifically,
among those with complete pathologic complete response, the
patients continued to do well and almost all remained disease-
free. However, of those with residual disease, early relapse and
death were more frequent among the basal-like and HER2+/
ER subtypes. This may well reflect the importance of the
adjuvant endocrine therapy that most luminal tumors received
and most basal-like and HER2+/ER did not. Thus, it may be
easier to achieve pathologic complete response in basal-like and
HER2+/ER tumors, but if pathologic complete response is not
achieved, they are more likely to relapse early and die. This is in
keeping with the emerging understanding that advances in
chemotherapy primarily affect relapses within the first few years
after diagnosis (4), which is when the fast-growing ER
subtypes are more likely to relapse. Our finding of particularly
poor outcome in basal-like and HER2+/ER subtypes with
residual disease after chemotherapy supports efforts to further
improve these outcomes and suggests that continued treat-
ments may be necessary. It is reasonable to assume that
trastuzumab will shift the HER2+/ER subtype survival curves
upward (18–20); however, we still lack targeted therapies for
the basal-like patients. Interestingly, although this study is not
large enough for direct comparisons within the luminal
subtypes, the clinical and pathologic response to chemotherapy
was higher in the luminal B subtype defined by both hormone
receptor and HER2 expression than in the luminal A subtype.
Given the low proportion of luminal A tumors that achieve
pathologic complete response, it is possible that this is a less
useful intermediate end point for outcome among luminal A
tumors compared with other subtypes. Luminal B tumors
virtually always have high recurrence scores (21), which is a
gene expression–based model that is associated with chemo-
sensitivity (17, 22).
There are caveats to this study. The entire patient set received
four cycles of AC as initial neoadjuvant therapy; however, the
majority received additional neoadjuvant chemotherapy that
primarily included paclitaxel. Thus, although the clinical
response rates were not affected, the pathologic responses
reflect the effects of the entire chemotherapy regimen. Because
the chemotherapy regimen did not statistically differ by sub-
type and the findings were consistent across clinical and
pathologic responses, these differences in treatment should not
confound our primary findings. However, it should be taken
into account when considering the pathologic response rate.
Another potential caveat to the generalizability of these
findings is with regards to HER2+ patients. At the time of this
study, there was a clinical trial incorporating trastuzumab into
neoadjuvant therapy at the University of North Carolina.
Because the inclusion of a biological therapy would confound
the clinical and pathologic response assessments, all of those
patients were excluded from this report. It is possible that
patients at higher risk would be more likely to participate in
such a trial, thereby biasing our HER2+ cohort to lower risk
tumor. We do not believe that this significantly affected our
results because we did not see a difference in tumor stage at
presentation by subtype, and because our results were
qualitatively similar to those of Rouzier and colleagues in this
respect (5). The exclusion of trastuzumab-treated patients,
however, certainly decreased the size of the HER2+ cohort
included in this study.
In summary, we have found that patients with the basal-like
and HER2+/ER subtype of breast cancer have higher
sensitivity to neoadjuvant anthracycline-based chemotherapy
than the luminal subtype, and have higher rates of patho-
logic complete response. Those patients who achieved a
pathologic complete response had a highly favorable out-
come. However, despite this sensitivity, the basal-like and
HER2+/ER subtypes still showed the same poor prognosis
as others have found before, with high relapse rates among
those who did not achieve pathologic complete response.
Targeted treatment analogous to endocrine therapy for lumi-
nal/ER+ patients is needed for these two subtypes. We now
have such a treatment for patients with the HER2+/ER
subtype (18–20), but not for patients with the basal-like breast
cancer subtype.
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